The present invention relates to novel processes for the preparation of N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyro!e-3-carboxamide and salts thereof, in particular N-[2-(diethylamino)ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-...
Anhydrous, crystalline forms of thalidomide having high polymorphic purity.
Documents
List of share holders, debenture holders;-23072020
Directors report as per section 134(3)-23072020
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-23072020
Optional Attachment-(1)-23072020
Form AOC-4-23072020_signed
Form MGT-7-23072020_signed
List of share holders, debenture holders;-26102019
Directors report as per section 134(3)-26102019
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-26102019
Optional Attachment-(1)-26102019
Form MGT-7-26102019_signed
Form AOC-4-26102019_signed
Form INC-22-11042019_signed
Copies of the utility bills as mentioned above (not older than two months)-11042019
Certificate from a Chartered Accountant in practice for calculation of the average annual turnover during the relevant period in case of conversion is on the basis of such criteria.-11042019
Proof of Registered Office address(Conveyance/Lease deed/Rent Agreement along with the rent receipts) etc-11042019
Copy of board resolution authorizing giving of notice-11042019
List of share holders, debenture holders;-27102018
Form MGT-7-27102018_signed
Form ADT-1-26102018_signed
Directors report as per section 134(3)-26102018
Optional Attachment-(1)-26102018
List of share holders, debenture holders;-26102018
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-26102018